RxDoctor Payments Data

Howard Goodman, MD

Gynecologic Oncology · West Palm Beach, FLNPI 1114926904

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.5% of the total across 209 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 8.3% — the pattern of someone who eats at a lot of different presentations.

$4,963in general payments, 2019–2025

Across 209 payments — averaging $23.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$411
  • Johnson & Johnson$353
  • Seagen Inc.$346
  • GSK$252
  • Eisai Inc.$234
  • Merck$232
  • plus $3K from 54 others
$37,555in research payments, 2019–2025

Across 33 payments — averaging $1138.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$28K
  • AstraZeneca$9K

What the payments were for

  • Consulting fees$120%
  • Food & beverage$4,79297%
  • Education$1603%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)17$411
Johnson & Johnson(2 entities)16$353
Seagen Inc.16$346
GSK14$252
Eisai Inc.10$234
Merck14$232
Intuitive Surgical4$228
LSI Solutions Inc2$215
Genentech USA, Inc.7$185
Bayer7$159
Bristol Myers Squibb8$158
Davol Inc.1$148
Daiichi Sankyo Inc.6$146
Novartis7$129
Takeda Pharmaceuticals U.S.A., Inc.5$122
Momentis Surgical Inc.1$109
Incyte Corporation5$104
Hologic Sales And Service, LLC1$99
Pharmacyclics LLC, An Abbvie Company5$96
Myriad Genetic Laboratories, Inc.5$90
Tempus AI, Inc4$86
Beigene USA, Inc.3$60
Dendreon Pharmaceuticals LLC2$57
Astellas Pharma US Inc3$54
Tersera Therapeutics LLC2$48
Sanofi2$43
Servier Pharmaceuticals LLC2$42
AbbVie2$42
Aurobindo Pharma USA, Inc.2$38
Lilly USA, LLC2$36
Ipsen Biopharmaceuticals, Inc2$35
Medtronic1$33
Taiho Oncology, Inc.2$32
Coherus Oncology, Inc.1$30
Sobi, Inc2$30
Immunogen, Inc.1$28
Janssen Scientific Affairs, LLC1$25
Sun Pharmaceutical Industries Inc.1$25
Deciphera Pharmaceuticals Inc.1$25
Sumitomo Pharma America, Inc.1$24
Azurity Pharmaceuticals, Inc.1$24
Springworks Therapeutics, Inc.1$22
Aspira Women's Health Inc2$22
Tesaro, Inc.1$21
Kyowa Kirin, Inc.1$21
Mylan Institutional Inc.1$20
EMD Serono, Inc.1$20
Helsinn Therapeutics (U.S.), Inc.1$19
Regeneron Healthcare Solutions, Inc.1$19
Sirtex Medical Inc1$18
E.r. Squibb & Sons, L.L.C.1$17
TG Therapeutics, Inc.1$17
Pfizer1$17
Exelixis Inc.1$16
Legend Biotech USA Inc.1$15
Recordati_rare_diseases_inc.1$15
Morphosys, US Inc.1$15
Stemline Therapeutics Inc.1$15
Agios Pharmaceuticals, Inc.1$14
Heron Therapeutics, Inc.1$9

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,963 in reported general payments places this provider in the 55th percentile of 117 gynecologic oncology providers in Florida.

See all gynecologic oncology providers in Florida

Medicare billing

Part B allowed, 2024
$141,190
Medicare patients
268
Services billed
916

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProgesteroneProgesterone, Micronized14$344
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen62$291
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav14$106

Paid to pharmacies, not to this prescriber.

Other gynecologic oncology in West Palm Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →